Cancer Clinical Trials

10,316 recruitingLast updated: June 6, 2026

There are 10,316 actively recruiting cancer clinical trials across 128 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Houston, Texas, United States, Shanghai, Shanghai Municipality, China. Updated daily from ClinicalTrials.gov.


Cancer Trials at a Glance

10,316 actively recruiting trials for cancer are listed on ClinicalTrialsFinder across 6 cities in 128 countries. The largest study group is Phase 2 with 2,878 trials, with the heaviest enrollment activity in New York, Houston, and Shanghai. Lead sponsors running cancer studies include Fudan University, M.D. Anderson Cancer Center, and Memorial Sloan Kettering Cancer Center.

Treatments under study

About Cancer Clinical Trials

Looking for clinical trials for Cancer? There are currently 905 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 10,316 trials

Recruiting

Natural History Study of Children and Adults With Medullary Thyroid Cancer

Medullary Thyroid Cancer
National Cancer Institute (NCI)259 enrolled1 locationNCT01660984
Recruiting
Phase 2

The Role of 68-Gallium-DOTATATE-PET/CT in the Imaging of Metastatic Thyroid Cancer

Metastic Thyroid Cancer
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)54 enrolled1 locationNCT04927416
Recruiting
Phase 1

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urothelial CancerBladder CancerGenitourinary Cancer+2 more
National Cancer Institute (NCI)100 enrolled1 locationNCT04235777
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled253 locationsNCT07061977
Recruiting

Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy

InfertilityAcute Ovarian FailureEarly Menopause And Infertility In Females After Treatment For Childhood Cancer
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)100 enrolled1 locationNCT05440617
Recruiting
Phase 2

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled222 locationsNCT05136196
Recruiting
Phase 3

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer
Pfizer900 enrolled240 locationsNCT06629779
Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled331 locationsNCT07028853
Recruiting
Phase 1Phase 2

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting

Patient-Centered Assessment of Symptoms and Outcomes

Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Janssen Cilag S.A.S.270 enrolled1 locationNCT07451002
Recruiting

Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer

Kidney CancerRenal Tumor HistologyCutaneous Leiomyoma
National Cancer Institute (NCI)1,130 enrolled1 locationNCT00050752
Recruiting
Phase 2

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Lung Cancer - Non Small Cell SquamousLung Cancer - Non Small Cell Non-Squamous
Merus B.V.180 enrolled24 locationsNCT07353957
Recruiting

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer
Centre Paul Strauss60 enrolled1 locationNCT05328024
Recruiting

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Prostate CancerProstatic Neoplasms
National Cancer Institute (NCI)300 enrolled1 locationNCT01834001
Recruiting
Phase 2

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Central Nervous System DiseasesBrain CancerGlioblastoma Multiforme (GBM)+4 more
Black Diamond Therapeutics, Inc.162 enrolled10 locationsNCT07326566
Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Non-small Cell Lung CancerMultiple MyelomaLymphoma, Non-Hodgkin+2 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting
Phase 1Phase 2

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

CancerBrain Tumor
National Cancer Institute (NCI)96 enrolled1 locationNCT05588141
Recruiting
Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting
Phase 2

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Head and Neck CancerHearing Loss
National Institute on Deafness and Other Communication Disorders (NIDCD)224 enrolled5 locationsNCT04915183